BS_R6WNEEE4
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 18.72
- os_event
- false
- age_years
- 4.041
- sex
- F
- race
- White
- new_clusters
- S2
- umap1_2d
- -0.726630525
- umap2_2d
- -9.36396429
- umap1_3d
- -3.628069614
- umap2_3d
- -1.148547894
- umap3_3d
- 5.757273301
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.490
- MYC_TARGETS_V1+0.370
- INTERFERON_GAMMA_RESPONSE+0.360
- MYC_TARGETS_V2+0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.320
- UV_RESPONSE_DN+0.320
- OXIDATIVE_PHOSPHORYLATION+0.280
- NOTCH_SIGNALING+0.260
- COAGULATION+0.250
- BILE_ACID_METABOLISM+0.230
Top 10 suppressed
- SPERMATOGENESIS-0.170
- MITOTIC_SPINDLE-0.150
- PI3K_AKT_MTOR_SIGNALING-0.120
- G2M_CHECKPOINT-0.100
- ESTROGEN_RESPONSE_LATE-0.060
- HEME_METABOLISM-0.060
- ANGIOGENESIS-0.050
- HEDGEHOG_SIGNALING-0.050
- MTORC1_SIGNALING-0.050
- TGF_BETA_SIGNALING-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C884FB38-DE5C-48BA-95F1-4ABD2991E833 | — | — | 0.760 |
| 2 | MDT-AP-2377 | Med | Medulloblastoma | 0.758 |
| 3 | MDT-AP-2822 | Med | Medulloblastoma | 0.732 |
| 4 | BS_RSRPX3S8 | Med | Medulloblastoma | 0.730 |
| 5 | SRR15030861 | — | — | 0.719 |
| 6 | MDT-AP-0348 | Med | Medulloblastoma | 0.718 |
| 7 | MDT-AP-2102 | Med | Medulloblastoma | 0.718 |
| 8 | MDT-AP-2589 | Med | Medulloblastoma | 0.718 |
| 9 | SRR934877 | — | — | 0.717 |
| 10 | SRR3147741 | — | — | 0.714 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.330 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.320 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.140 | Idelalisib | — uncovered |
| COMPLEMENT | 0.130 | Inavolisib | — uncovered |